Training and passion sit at the core of the University of Washington Medical Center heart team's mission. Learn how this national training site for Protected PCI with hemodynamic support is teaching: hands-on, in-depth, in-person, head to head.

The FDA granted a 510(k) clearance on Oct. 6 to the CorPath System for use during PCIs performed via radial access.

For the past few years, the Transcatheter Cardiovascular Therapeutic (TCT) conference has focused on structural heart disease as a major subspecialty in interventional cardiology. This year’s conference, which runs from Oct. 10 to 15 in San Francisco, will have more of an emphasis on coronary intervention, according to TCT co-director Gregg W. Stone, MD.

The FDA approved the Synergy bioabsorbable polymer drug-eluting stent system on Oct. 5 to treat coronary artery disease. The Synergy stent is the first FDA-approved bioabsorbable polymer drug-eluting stent system, according to Boston Scientific, its manufacturer. The stent was approved in Europe in 2012.

Good Samaritan Hospital in L.A. looks to its managers to preserve that margin by slashing supply costs without compromising clinical quality.

High-risk PCI patients have new options at Einstein Healthcare Network in Philadelphia with the Impella 2.5, a miniature heart pump for use in elective and urgent high-risk PCI procedures.

The FDA has issued a Class I recall of a select number of SynCardia Systems Total Artificial Heart Freedom driver.

Corindus Vascular Robotics released a documentary on Sept. 16 to promote its CorPath System, the only FDA-cleared device for robotic-assisted PCI.